Purple Biotech (PPBT) Equity Ratio (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Equity Ratio data on file, last reported at 0.67 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.67, down 27.03% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.67 (down 27.03% YoY), and the FY2025 annual result was 0.55, down 38.14% from the prior year.
• Equity Ratio climbed to 0.67 in Q1 2026 per PPBT's latest filing, from 0.55 in the prior quarter.
• Over five years, Equity Ratio peaked at 2.76 in Q2 2023 and troughed at 0.55 in Q4 2025.
• A 5-year average of 1.01 and a median of 0.86 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio jumped 114.64% in 2022, then sank 70.44% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.86 in 2022, then slipped by 10.22% to 0.77 in 2023, then increased by 14.78% to 0.89 in 2024, then tumbled by 38.14% to 0.55 in 2025, then climbed by 21.95% to 0.67 in 2026.
• Business Quant data shows PPBT's Equity Ratio at 0.67 in Q1 2026, 0.55 in Q4 2025, and 0.84 in Q3 2025.